Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma
Introduction: Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy that specifically targets cancer cells. In NIR-PIT, antibody-photo-absorber-conjugates (APCs), specific for cancer antigens, target cancer cells. APCs that bind to antigens and are irradiated with NIR-light kill targe...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | EJC Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772610X25000212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850218327456088064 |
|---|---|
| author | Jimei Zhao Kohei Nakajima Masahiro Ueki Yukayo Terashita Shinsuke Hirabayashi Yuko Cho Mikako Ogawa Atsushi Manabe |
| author_facet | Jimei Zhao Kohei Nakajima Masahiro Ueki Yukayo Terashita Shinsuke Hirabayashi Yuko Cho Mikako Ogawa Atsushi Manabe |
| author_sort | Jimei Zhao |
| collection | DOAJ |
| description | Introduction: Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy that specifically targets cancer cells. In NIR-PIT, antibody-photo-absorber-conjugates (APCs), specific for cancer antigens, target cancer cells. APCs that bind to antigens and are irradiated with NIR-light kill targeted cells. NIR-PIT has been clinically applied to head and neck squamous cell carcinoma in Japan, but not to pediatric cancers. Generally, neuroblastoma and osteosarcoma express disialoganglioside (GD2), making NIR-PIT that targets GD2 an additional treatment option. Methods: Antihuman GD2 monoclonal antibody (clone 3F8) was conjugated with photo-absorber, IRDyeⓇ 700DX (IR700). A human neuroblastoma cell (SK-N-SH) was used for in vitro and in vivo experiments, whereas human osteosarcoma cells (NOS-10, MG-63) were utilized for in vitro experiments. Microscopy and flow cytometry were used to evaluate cell death after NIR-PIT, and longitudinal measurement of tumor size and histological observation were utilized to assess the effect of NIR-PIT on the xenograft model. Results: EthD-1 staining after NIR-PIT confirmed the morphological changes (swelling and bleb formation) observed by microscopy and cell death. Flow cytometry verified the significant increase in dead cells after NIR-PIT. Tumor growth in the mice model was significantly inhibited at day 10 of the experiment and destroyed tumor tissue was histologically observed in the PIT-treated mice. Conclusion: The efficacy of NIR-PIT with antiGD2 antibody for neuroblastoma and osteosarcoma was indicated. Additionally, NIR-PIT efficacy against neuroblastoma was indicated by the mice model in vivo. Therefore, further experiments and more effective protocols should be considered for clinical application. |
| format | Article |
| id | doaj-art-89ddd13b5d6c413dbb004e135383db81 |
| institution | OA Journals |
| issn | 2772-610X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Paediatric Oncology |
| spelling | doaj-art-89ddd13b5d6c413dbb004e135383db812025-08-20T02:07:47ZengElsevierEJC Paediatric Oncology2772-610X2025-06-01510023310.1016/j.ejcped.2025.100233Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcomaJimei Zhao0Kohei Nakajima1Masahiro Ueki2Yukayo Terashita3Shinsuke Hirabayashi4Yuko Cho5Mikako Ogawa6Atsushi Manabe7Department of Pediatrics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; Department of Pediatric Dentistry, Graduate School of Dental Medicine, Hokkaido University, Sapporo, JapanLaboratory of Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, JapanDepartment of Pediatrics, Hokkaido University Hospital, Sapporo, JapanDepartment of Pediatrics, Hokkaido University Hospital, Sapporo, JapanDepartment of Pediatrics, Hokkaido University Hospital, Sapporo, JapanDepartment of Pediatrics, Hokkaido University Hospital, Sapporo, JapanLaboratory of Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, JapanDepartment of Pediatrics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; Department of Pediatrics, Hokkaido University Hospital, Sapporo, Japan; Correspondence to: Department of PediatricsHokkaido University Graduate School of MedicineKita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan.Introduction: Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy that specifically targets cancer cells. In NIR-PIT, antibody-photo-absorber-conjugates (APCs), specific for cancer antigens, target cancer cells. APCs that bind to antigens and are irradiated with NIR-light kill targeted cells. NIR-PIT has been clinically applied to head and neck squamous cell carcinoma in Japan, but not to pediatric cancers. Generally, neuroblastoma and osteosarcoma express disialoganglioside (GD2), making NIR-PIT that targets GD2 an additional treatment option. Methods: Antihuman GD2 monoclonal antibody (clone 3F8) was conjugated with photo-absorber, IRDyeⓇ 700DX (IR700). A human neuroblastoma cell (SK-N-SH) was used for in vitro and in vivo experiments, whereas human osteosarcoma cells (NOS-10, MG-63) were utilized for in vitro experiments. Microscopy and flow cytometry were used to evaluate cell death after NIR-PIT, and longitudinal measurement of tumor size and histological observation were utilized to assess the effect of NIR-PIT on the xenograft model. Results: EthD-1 staining after NIR-PIT confirmed the morphological changes (swelling and bleb formation) observed by microscopy and cell death. Flow cytometry verified the significant increase in dead cells after NIR-PIT. Tumor growth in the mice model was significantly inhibited at day 10 of the experiment and destroyed tumor tissue was histologically observed in the PIT-treated mice. Conclusion: The efficacy of NIR-PIT with antiGD2 antibody for neuroblastoma and osteosarcoma was indicated. Additionally, NIR-PIT efficacy against neuroblastoma was indicated by the mice model in vivo. Therefore, further experiments and more effective protocols should be considered for clinical application.http://www.sciencedirect.com/science/article/pii/S2772610X25000212Near-infrared photoimmunotherapyNeuroblastomaOsteosarcomaGD2Pediatric cancerCancer treatment |
| spellingShingle | Jimei Zhao Kohei Nakajima Masahiro Ueki Yukayo Terashita Shinsuke Hirabayashi Yuko Cho Mikako Ogawa Atsushi Manabe Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma EJC Paediatric Oncology Near-infrared photoimmunotherapy Neuroblastoma Osteosarcoma GD2 Pediatric cancer Cancer treatment |
| title | Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma |
| title_full | Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma |
| title_fullStr | Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma |
| title_full_unstemmed | Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma |
| title_short | Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma |
| title_sort | near infrared photoimmunotherapy using antigd2 antibody for neuroblastoma and osteosarcoma |
| topic | Near-infrared photoimmunotherapy Neuroblastoma Osteosarcoma GD2 Pediatric cancer Cancer treatment |
| url | http://www.sciencedirect.com/science/article/pii/S2772610X25000212 |
| work_keys_str_mv | AT jimeizhao nearinfraredphotoimmunotherapyusingantigd2antibodyforneuroblastomaandosteosarcoma AT koheinakajima nearinfraredphotoimmunotherapyusingantigd2antibodyforneuroblastomaandosteosarcoma AT masahiroueki nearinfraredphotoimmunotherapyusingantigd2antibodyforneuroblastomaandosteosarcoma AT yukayoterashita nearinfraredphotoimmunotherapyusingantigd2antibodyforneuroblastomaandosteosarcoma AT shinsukehirabayashi nearinfraredphotoimmunotherapyusingantigd2antibodyforneuroblastomaandosteosarcoma AT yukocho nearinfraredphotoimmunotherapyusingantigd2antibodyforneuroblastomaandosteosarcoma AT mikakoogawa nearinfraredphotoimmunotherapyusingantigd2antibodyforneuroblastomaandosteosarcoma AT atsushimanabe nearinfraredphotoimmunotherapyusingantigd2antibodyforneuroblastomaandosteosarcoma |